Finding markers in the blood to predict cognitive decline in Parkinson's disease.
Identifying Metabolomic Markers in Conversion to Cognitive Impairment in Parkinson's Disease
This study is looking for clues in the blood and spinal fluid of people with Parkinson's disease to help predict when they might start having trouble with thinking and memory, so that doctors can better plan treatments and trials for those affected.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-11077861 on NIH RePORTER |
What this research studies
This research aims to identify specific metabolomic markers in the blood and cerebrospinal fluid of patients with Parkinson's disease (PD) to predict the onset of cognitive impairment. By utilizing advanced techniques like gas chromatography mass-spectroscopy (GC-MS) and liquid chromatography-mass spectroscopy (LC-MS), the study will analyze samples from patients who have been monitored over time. The goal is to establish a clear link between metabolomic profiles and the transition from normal cognition to cognitive impairment, which could inform treatment strategies and clinical trial designs.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease who currently do not exhibit cognitive impairment.
Not a fit: Patients with advanced cognitive impairment or those without a diagnosis of Parkinson's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection and intervention strategies for cognitive decline in Parkinson's disease patients.
How similar studies have performed: Previous research has shown promise in identifying biomarkers for cognitive decline in neurodegenerative diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Yamasaki, Tritia — University of Kentucky
- Study coordinator: Yamasaki, Tritia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.